Anaptysbio (ANAB) Accumulated Expenses (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Accumulated Expenses data on file, last reported at $32.1 million in Q1 2026.

• Quarterly Accumulated Expenses fell 10.81% year-over-year to $32.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.1 million (down 10.81% YoY) and the FY2025 annual result came in at $32.7 million, down 17.28% from the prior year.
• Accumulated Expenses fell to $32.1 million in Q1 2026, from $32.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $39.5 million in Q4 2024 to a low of $15.8 million in Q1 2022.
• A 5-year average of $29.4 million and a median of $31.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 110.39% — and 2025, when it declined 17.28%.
• Tracing ANAB's Accumulated Expenses over 5 years: stood at $21.6 million in 2022, then jumped by 43.15% to $31.0 million in 2023, then gained by 27.56% to $39.5 million in 2024, then decreased by 17.28% to $32.7 million in 2025, then retreated by 1.86% to $32.1 million in 2026.
• The last three Accumulated Expenses figures came in at $32.1 million (Q1 2026), $32.7 million (Q4 2025), and $33.2 million (Q3 2025), per Business Quant data.